Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 20/20 | 0.78 |
| ▸ | EGFR | P00533 | 1/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.78 |
| ▸ | JAK3 | P52333 | 1/20 | 0.78 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.78 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.78 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.78 |
| ▸ | RAF1 | P04049 | 17/20 | 0.63 |
| ▸ | ABL1 | P00519 | 2/20 | 0.59 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.59 |
| ▸ | FLT3 | P36888 | 2/20 | 0.59 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.59 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.59 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.59 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.59 |
| ▸ | HIPK1 | Q86Z02 | 2/20 | 0.59 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 0.59 |
| ▸ | ERN1 | O75460 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24579569 | 0.88 | BRAF (1.00) | BRAFEGFRCYP3A4JAK3MAPK10 | |
| SCHEMBL29735965 | 0.88 | BRAF (1.00) | BRAFEGFRCYP3A4JAK3MAPK10 | |
| SCHEMBL12023652 | 0.86 | BRAF (0.73) | BRAFEGFRCYP3A4JAK3MAPK10 | |
| SCHEMBL24579579 | 0.85 | BRAF (0.86) | BRAFEGFRCYP3A4JAK3MAPK10 | |
| SCHEMBL21875507 | 0.83 | BRAF (0.61) | BRAFEGFRCYP3A4JAK3MAPK10 | |
| SCHEMBL12023894 | 0.83 | BRAF (0.60) | BRAFEGFRCYP3A4JAK3MAPK10 | |
| SCHEMBL12023951 | 0.82 | PTGS2 (0.68) | BRAFEGFRCYP3A4JAK3MAPK10 | |
| SCHEMBL12023953 | 0.81 | BRAF (0.61) | BRAFEGFRCYP3A4JAK3MAPK10 | |
| SCHEMBL1730222 | 0.80 | PTGS2 (0.66) | BRAFEGFRCYP3A4JAK3MAPK10 | |
| SCHEMBL3811246 | 0.80 | RAF1 (0.61) | BRAFRAF1ABL1FGFR1FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110301160-A1 | Inhibitors of P38 and Methods of Using the Same | ARQULE, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301160-A1 | Inhibitors of P38 and Methods of Using the Same | ARQULE, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| EP-1633758-B1 | IMIDAZOTHIAZOLES AND IMIDAZOXAZOLE DERIVATIVES AS INHIBITORS OF P38 | ARQULE INC (US) | 2011-11-23 | — | — | EP | disclosed |
| US-7902192-B2 | Inhibitors of P38 and methods of using the same | ARQULE, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902192-B2 | Inhibitors of P38 and methods of using the same | ARQULE, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-20070270418-A1 | Inhibitors of P38 and Methods of Using the Same | ARQULE, INC. | 2007-11-22 | — | — | US | disclosed |
| US-20070270418-A1 | Inhibitors of P38 and Methods of Using the Same | ARQULE, INC. | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270418-A1 | Inhibitors of P38 and Methods of Using the Same | MAPK1, MAPK8, MAPK7 | BRAF 179/4885EGFR 3772/4885CYP3A4 4606/4885 |
| US-20110301160-A1 | Inhibitors of P38 and Methods of Using the Same | MAPK1, MAPK7, MAPK8 | BRAF 154/4885EGFR 3656/4885CYP3A4 4483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.